Prognostic Factors of Surgical Complications and Overall Survival of Patients with Metastatic Spinal Tumor by Czigléczki, Gábor et al.
Journal reference: World Neurosurg. (2018) 113:e20-e28.
https://doi.org/10.1016/j.wneu.2018.01.092
Prognostic factors of surgical complications and overall survival
of patients with metastatic spinal tumor
Gábor Czigléczki MD. (1, 2), Tamás Mezei (2), Péter Pollner PhD. (3), Anna Horváth MD.,
PhD (4), Péter Banczerowski MD., PhD. (1, 2)
1: National Institute of Clinical Neurosciences, Budapest, Hungary
2: Department of Neurosurgery, Semmelweis University, Budapest, Hungary
3: MTA-ELTE Statistical and Biological Physics Research Group, Hungarian Academy of 
Sciences, Eötvös University, Statistical and Biological Physics Research Group, Budapest, 
Hungary
4: 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Correspondence author:
Gábor Czigléczki MD
National Institute of Clinical Neurosciences, Hungary, Budapest 
1145, Amerikai út 57.
Phone: +36 1 467 9300
Email: gczigleczki@gmail.com
Key words
spinal metastases, prognostic factors, overall survival time, prognosis scoring systems, risk
factors of surgical complications
Abstract
OBJECTIVE:  Oncologic  treatments  increase the incidence  of spinal  metastases.  Surgical
treatment of spinal metastases results in a high complication rate, which must set against the
expected benefits. The aim of this article was to study the effect of several prognostic factors
on surgical complications and survival time using an extended database of patients with spinal
metastases. 
METHODS:  This retrospective study comprised 337 patients  with spinal  metastases who
were surgically treated between 2008 and 2015. Demographic and clinical features, oncologic
histories,  surgical  interventions,  and  end  results  were  collected.  Descriptive  statistical
methods were used to analyze the cohort of patients. Kaplan-Meier formula and log-rank test
were used to examine overall survival times.
RESULTS:  Median  overall  survival  time  was  222  days  (range,  175-274  days).  Age,
preoperative motor disorders, preoperative Frankel grade categories, Karnofsky performance
scale, type of primary tumor, and presence of internal metastasis had a significant negative
effect on overall survival. Complications such as bleeding or need for intensive care could be
predicted preoperatively based on preoperative performance status, type of primary tumor,
affected vertebral levels, and type of surgical interventions.
CONCLUSION:  Spinal metastatic  disease is  a challenging surgical  problem. If  the exact
prognostic factors are known preoperatively,  surgical outcome and overall  survival can be
predicted  more  precisely.  Our  results  could  provide  a  basis  for  a  future  multicenter
prospective study to determine the best treatment protocol for patients with spinal metastases.
Introduction
Longer life expectancy of patients with cancer and successful oncologic treatments
have resulted in an increased incidence of spinal metastases  [1-4]. Spinal metastases can be
expected in 70% of patients  with a cancer diagnosis, and neurologic symptoms related to
spinal cord compression may develop in 10% [5]. The main goals of surgical treatment should
be  to  improve  mechanical  stability,  decompress  neural  structures,  relieve  neurological
symptoms, and improve quality of life; however, most of the underlying cancer types and
stages  carry  dismal  prognoses  [2,  6].  Surgical  treatment  of  spinal  metastases  results  in  a
complication rate of 20-30% which must be considered against the expected benefits [2, 7]. If
the exact risk and complication factors are known preoperatively, surgical outcome can be
predicted more precisely. Scoring systems such as Tokuhashi [8-10], Tomita [11], Bauer [12,
13] and Linden  [14] systems are widely used in clinical practice to offer the best surgical
strategy based on the patient’s prognostic factors. Using an extended database of patients who
underwent surgical interventions because of spinal metastases, the aim of this article was to
study the effect of the risk factors of 4 prognosis scoring systems on the survival time of
patients with metastatic spinal tumors. Furthermore, we aimed to investigate the prediction
ability of scoring systems for prognosis and to possibly evaluate new risk factors to extend the
prediction ability of various prognostic systems in the future. Correlating risk factors with the
main surgical complications were also examined.
Methods
Patient database
We created a retrospective database of 337 patients who underwent spinal surgery for
spinal  metastases  at  the  National  Institute  of  Clinical  Neuroscience,  Department  of
Neurosurgery, Semmelweis University, Budapest, Hungary, between 2008 and 2015. Surgical
intervention  was  the  only  criterion  of  admission  for  the  study.  Of  the  382  interventions
identified in the inquiry, 337 patient histories were compiled; 38 patients had records with
multiple  surgical  interventions  (31  patients  with  2  interventions  and  7  patients  with  3
interventions; none of the patients had >3 interventions). 
Most  of  the  examined  risk  factors  are  presented  in  prognosis  prediction  systems
(revised  Tokuhashi,  Tomita,  modified  Bauer,  and  van  der  Linden  scores)  (Tables  1-4.).
Several other factors from the patients' history were also collected. Demographic and baseline
clinical variables of interest included sex and age at time of surgery. Baseline functional status
was measured with the Karnofsky performance scale (KPS). Further data recorded about the
status of the patient included main clinical symptoms, presence of motor or sensory deficit,
Frankel scores, extraspinal bony metastases, and metastases in the internal organs. Regarding
the surgical intervention, we have extracted the following factors: affected vertebral levels,
steps of intervention, postoperative condition, and period of hospital stay. Each patient history
consisted  of  data  about  the  metastasis  (categorized  by primary  site  of  origin),  histologic
diagnoses, and other comorbidities. Finally, 2 main types of complications were examined. A
bleeding  complication  was  defined  as  an  intraoperative  or  postoperative  hemorrhage  that
necessitated  blood  transfusion.  Other  complications  were  defined  as  the  need  for
postoperative intensive care related to difficulties because of the surgery in at least 1 of the 7
main organ systems (cardiovascular, respiratory, central nervous system, gastrointestinal tract,
renal, hematologic, or metabolic).
Statistical analysis
Descriptive statistics were used to describe the cohort of patients. The selected factors and
their clustering were not modified after the first statistical evaluation to avoid distortion of
retrospective  results.  Fisher  exact  tests  were  employed to identify  significant  associations
between  covariants  of  interest  and  categorical  outcomes  (complications).  Kaplan-Meier
formula and log-rank test were used to examine overall survival (OS). Results with P values
<0.05 were considered statistically significant in the final analysis. In the post hoc analysis,
we applied statistical corrections (Bonferroni correction) where combinatorial selection was
used. R software (R Foundation for Statistical Computing, Vienna, Austria) was used for all
statistical analyses.[32]
Results
Survival data and rate of complications
We identified 337 patients, 199 (59.1%) men and 138 (40.9%) women, with a mean
age of 63 ± 12 years (range, 15–88 years). OS was calculated by the Kaplan-Meier formula
(Table 5). Median OS (amount of time when 50% of the patients have died) was 222 days;
the 95% confidence interval ranged from 175 to 274 days. Because some patients were alive
at the time of data taking, we provide the restricted mean (upper limit = 2739 days) for the OS
time as 660.3 days (with SE 56.7 days). The Kaplan-Meier curve with censored data and with
pointwise  95%  confidence  intervals  is  presented  in  Figure  1.  Of  the  337  patients,  135
(40.06%)  had  some  complication  during  or  right  after  the  surgery  (11  patients  needed
intensive  care  only,  102  had  bleeding  only,  and  22  had  both  bleeding  and  need  for
postoperative  intensive  care).  Some  patients  with  >1  intervention  may  have  had  both
complications during their history without having any intervention with 2 complications. 
Predictors of OS
Evaluating the predictors of OS, we calculated the OS value with the Kaplan-Meier
formula for each category,  and we examined several risk factors.  The significance of the
difference between subgroups was tested with the log-rank test. 
The subpopulations with specific values of the following factors differ significantly
from each other in OS according to the log-rank test: 
Age.  (subgroups:  <40,  40-50,  50-60,  60-70,  >70).  The  subgroups  of  age  were
significantly  different  from  each  other  (P=0.021).  The  subgroup  <40  (P=0.028)  was
associated with longer survival time (Figure 2).
Preoperative  motor  deficits (subgroups:  paresis,  paralysis,  none;  P=0.014).  The
paralysis subgroup (P=0.0068) was associated with a shorter survival (Figure 3.).
Frankel grade (subgroups: A, B, C, D, E; P=0.0223). Frankel A and B categories
(P=0.00293) were associated with shorter survival (Figure 4). 
KPS (subgroups: 10%-40%, 50%-70%, 80%-100%; P=0.0001). For KPS, we found 2
subgroups that are different from the rest of the population. The poor condition group (10%-
40%;  P=0.00039)  had  a  shorter  survival,  and  the  good  condition  group  (80%-100%;
P=0.0004) had a longer survival (Figure 5).
The type of the primary tumor significantly affected patient survival (P<1e-6). From the
tested tumor categories, the most common primary tumor types in the population were lung
malignancies  (24.9%),  multiple  myeloma  (11.3%),  breast  cancers  (8.9%),  renal  cell
carcinomas (7.7%), and prostate malignancies (6.5%) (Table 6). From the solid types, lung
(P<1e-6)  (Figure 6a)  and the cervical  P=5e-6)  carcinomas  (Figure 6b) had a  significantly
poorer  prognosis  compared with  the  other  tumors.  Among the  hematologic  malignancies,
multiple myeloma had a much better OS than the other types (p<1e-6) (Figure 6c).
Internal  metastasis  (subgroups:  no  metastasis,  surgically  removable,  surgically
unremovable;  P=0.0262).  The  surgically  unremovable  metastasis  category  has  shorter
survival than the other subgroups (P=0.0074) (Figure 7).
Number  of  metastasis  in  the  vertebral  body (subgroups:  1-2,  3-10)  significantly
affected  patient  survival  (P=0.0139).  Dissemination  of  the  disease  was  associated  with  a
worse prognosis (Figure 8).
For the following factors,  OS was not  significantly different  in the subgroups with given
values of the factors: 
1. sex (subgroups: female, male)
2. operation type (subgroups: palliative, excisional)
3. preoperative  sensory  deficits (subgroups:  no  deficit,  hypoesthesia,  hyperesthesia,
paresthesia, multiple sensory deficits)
4. symptoms at clinical presentation (subgroups: sensorial deficits, vegetative disorder,
motor deficits, pain, other symptoms)
5. affected vertebral levels (subgroups: sacral, lumbal, thoracic, cervical, multiplex),
6. extraspinal bone metastasis (subgroups by number of metastases: 0, 1, 2, more) 
Predictors of complications
Correlations between preoperative factors and complications (bleeding and need for
postoperative intensive care) were also tested.  Table 7  lists all factors that have at least 1
subcategory  in  which  the  odds  ratio  of  a  complication  is  either  significantly  high  or
significantly  low.  The  associations  between  the  complications  and  factor  values  were
identified  with  a  3-step  procedure.  First,  we  calculated  the  Fischer  exact  test  to  find
significant  co-occurrence  of  factors  and  complication  types  (bleeding  or  need  for
postoperative intensive care). Second, with a post hoc analysis, we selected the subcategory of
the  factor  type  and  the  complication  type  that  were  significantly  associated.  Finally,
associations with high P values were tested with Bonferroni correction.
Discussion
Modern  oncologic  treatment  and  developing  surgical  techniques  extend  the  life
expectancy of patients  with cancer,  allowing malignant  mutations  to eventually  grow and
metastasize [2, 11, 15]. The spinal column is the most frequently affected part of the skeletal
system in terms of metastasis [15-17]. Owing to the oncologic nature of the disease, surgery
alone is not sufficient to determine the most effective treatment method. A more personalized,
multifactorial approach is necessary to provide a better outcome for the patients by extending
survival time or improving the quality of life. Our research focused on surgery for metastatic
spinal tumors. We evaluated several preoperative factors that could affect the OS of patients
or predict  intraoperative and postoperative  complications.  The factors  were classified into
subgroups to examine connections between variations in details. 
Age, preoperative motor disorders, Frankel grade categories, KPS, type of the primary
tumor, presence of internal metastasis, and number of metastases in the vertebral body were
found to have a significant negative effect on OS. Eap et al [18] found increased age to be a
bad  prognostic  factor  for  survival,  which  our  results  also  confirm.  Preoperative  motor
disorders were previously reported to be a bad prognostic factor for survival [19, 20]. Another
important factor for survival is the speed of neurologic deficit. Rades et al.  [21, 22] showed
that slower development of the motor deficit (>14 days) before radiotherapy predicts better
functional outcome, and the length of development is a relevant prognostic factor. Fan et al.
[23] found the timing of surgical intervention is key to predicting the postoperative outcome.
They argued that the best surgical and functional outcome was observed for patients with
Frankel A functional status if the patients received treatment within 24 hours. In our cohort,
nearly half of the patients already had motor deficits at the time of presentation, but only
paralysis  was  an  indicator  of  significantly  shorter  survival.  Poor  preoperative  functional
status (Frankel grade system groups A and B, KPS 10%-40%) had a negative  impact  on
survival, and these results correlate with clinical experiences and expectations. Considering
the features of malignancies, expanded disease (if the number of metastases in the vertebral
column are >=2) or the presence of an inoperative  internal organ metastasis shortened the
expected  survival  time,  which  is  in  conjunction  with  the  findings  in  the  literature  [20].
Solitary metastases allow radical treatment resulting in better tumor control and increased OS.
Furthermore,  neurologic symptoms and pain could be treated  more effectively,  leading to
increased quality of life [24]. Our results support these findings, as significant change in OS
was observed if the number of vertebral metastases was >2 (Figure 8). From the group of
primary tumors types, lung and cervical carcinoma had significantly shortened the expected
survival;  however,  according  to  our  observations,  lung  tumors  should  be  examined  in
subgroups later because prognosis may vary greatly in the different pathologic subtypes of
lung cancers.
Our analysis revealed that sex, surgical complications, preoperative sensory deficits,
symptoms at clinical presentation, affected vertebral levels, and extraspinal bone metastases
did not have an effect on OS of patients. However, we emphasize that nearly one fourth of our
patients (25.6%) had pain only as the presenting symptom of their diseases, and many patients
were  treated  by  ineffectual  rheumatologic  methods  for  months  before  a  proper  imaging
examination  was  performed.  Hosono  et  al.  [25] found  that  intense  pain  is  also  a  bad
prognostic  factor  in  a  patient  with  cancer,  but  our  results  do  not  confirm these  findings
statistically.
Surgical complications occur in 25%-34% of operations for metastatic spinal diseases
[26].  Our investigation  focused on 2 main  types  of complications:  bleeding and need for
postoperative intensive care because of the poor postoperative status. Several articles studied
the typical volume of bleeding during surgery [27, 28]; however, the number of studies that
report blood losses by type of surgical interventions [29, 30] and tumor types is limited [28,
31]. Furthermore, only a few studies investigated a relatively larger series of patients [28, 29].
Kumar et al.  [28] proved that the type of primary tumor is a key factor for estimating the
amount of intraoperative blood loss, and an extended surgery is likely to increase the bleeding
complications. If risk factors for increased intraoperative bleeding are known preoperatively,
appropriate  preoperative  planning  allows  sufficient  intraoperative  and  postoperative
management of homeostasis and fluid balance and may reduce the prevalence of perioperative
morbidities  [28].  Our results  are  in agreement  with previous reports  [28,  29] and support
mainly  the  clinical  experiences  and  observations.  We  found  the  following  factors  to  be
associated with higher risk of bleeding: preoperative poor performance status, primary renal
tumor,  and corpectomy.  Renal  tumors  by  an  intense  vascular  endothelial  growth  factor
secretion and invasive marginal or en bloc tumor resections are known to be associated with
bleeding  [28]. The relationship between poor preoperative performance status and bleeding
can be explained by the poor general condition and homeostatic features of the patients. For
the prediction of need for postoperative intensive care, a very significant factor is  cervical
segment  involvement  with  a  nearly  7-fold  increased  risk  because  of  respiratory  system
complications, which is also in agreement with clinical experiences.
We examined the effect of several risk factors of prognosis scoring systems on OS
time of patients with spinal metastases, and we examined the prognostic factors of surgical
complications.  However,  this  study  is  limited  by  the  general  drawback  of  retrospective
statistical  evaluation  of  human  data.  Usually,  there  are  large  variations  in  intervention
responses if only a few factors or observations are fixed. In our retrospective analysis, we
were restricted to consider only available data, and hence further investigations could not be
made to distinguish between cases with similar input but different output values. The single
site  cohort  may  introduce  some  bias  in  the  data,  where  unrecorded  genetic  or  habitual
similarities between the cases could affect the results. 
Conclusions
The aim of the study was to  analyze an extended database of patients  with spinal
metastases who underwent surgical interventions. Our investigation mainly focused on risk
factors for surgical complications and prognostic factors of OS time. Age, preoperative motor
disorders, preoperative Frankel grade categories, KPS, type of primary tumor, and presence of
internal metastasis have a significant negative effect on OS. Complications such as bleeding
or  need  for  intensive  care  could  be  predicted  preoperatively  based  on  preoperative
performance status,  type of primary tumor,  affected vertebral  levels,  and type of surgical
interventions.  Spinal  metastatic  disease  still  remains  a  serious  and  challenging  surgical
problem, but early diagnosis and sufficient treatment may prevent serious complications and
result in longer survival. If the exact risk and prognostic factors are known preoperatively,
surgical outcome can be predicted more precisely. We believe our results could provide a
basis for a future  multicenter prospective study to determine the best treatment protocol for
patients with spinal metastases.
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Table list
Table 1. Revised Tokuhashi score
Predictive Factors Points
General condition (KPS)
Poor (KPS 10%-40%) 0
Moderate (KPS 50%-70%) 1
Good (KPS 80%-100%) 2
Number of extraspinal bone foci
>=3 0
1-2 1
0 2
Number of metastases in vertebral body
>=3  0
2 1
1 2
Metastases to major internal organs
Nonremovable 0
Removable 1
No metastasis   2
Primary site of cancer
Lung,  osteosarcoma,  stomach,  bladder,
esophagus, pancreas 
0
Liver, gallbladder, unidentified 1
Others  2
Kidney, uterus 3
Rectum 4
Thyroid, breast, prostate, carcinoid 5
Palsy
Frankel A, B (complete) 0
Predictive Factors Points
Frankel C, D (incomplete) 1
Frankel E (none) 2
Prognostic Categories Interpretation
0-8 points 85%  live  <6  months  -->  conservative
treatment or palliative surgery
9-11 points 73% live >6 months (and 30% live >1 year)
-->  palliative  surgery  or  (exceptionally)
excisional surgery
12-15 points  95%  live  >1  year  -->  excisional
surgery
KPS, Karnofsky performance scale.
Table 2. Tomita score
Predictive Factors Point(s)
Primary tumor
Slow growth (e.g., breast, prostate, thyroid) 1
Moderate growth (e.g., kidney, uterus) 2
Rapid  growth  (e.g.,  lung,  liver,  stomach,
colon, primary unknown)
4
Primary tumor
No visceral metastasis 0
Treatable 2
Untreatable  4
Bone metastasis (including spine)
Solitary/isolated 1
Multiple 2
Prognostic Categories (Points) Interpretation
2-3 Long-term  local  control  (mean
survival  50  months)  -->  wide  or
marginal excision
4-5 Mid-term  local  control  (mean
survival 23.5 months) --> marginal
or intralesional excision
6-7 Short-term  palliation  (mean
survival  15 months)  --> palliative
surgery
8-10 Terminal  care  (mean  survival  6
months)  -->  supportive  care,  no
surgery
Table 3. The modified Bauer score
Predictive Factors Point(s)
No visceral metastasis 1
No lung cancer 1
Primary  tumor  =  breast,  kidney,
lymphoma, multiple myeloma
1
1 solitary skeletal metastasis 1
Prognostic Categories (Points) Interpretation
0-1  4.8 monthsesupportive care, no surgery
2 18.2  monthseshort-term  palliation,  dorsal
surgery
3-4 28.4  monthsemid-term  local  control,
dorsoventral surgery
Table 4. van der Linden score
Predictive Factors Point(s)
Karnofsky Performance Status
80-100  2
50-70 1
20-40 0
Primary tumor
Breast 3
Prostate 2
Lung 1
Other  0
Visceral metastasis
No 1
Yes 0
Prognostic Categories (Points) Interpretation
0-3 4.8 monthseconservative therapy
4-5 13.1 monthsepalliative surgery
6 18.3 monthseexcisional surgery
Table 5. Overall survival data
Time Survival SE Lower 95% CI Upper 95% CI
30 days  0.924  0.0146  0.896 0.953
60 days  0.827  0.0209  0.787 0.869
90 days  0.748  0.0239  0.702 0.796
180 days  0.543  0.0276  0.492 0.6
1 year 0.389 0.0277 0.338 0.447
3 years  0.191  0.0249  0.148 0.247
5 years  0.145  0.0253  0.103 0.205
CI,  confidence
interval.
Table 6. Data of patients categorized by the type of primary tumors
Tumor Type Number of Patients (%)
All 337 (100)
Bladder cancer  7 (2.1)
Breast cancer 30 (8.9)
Cervical carcinoma 4 (1.2)
Colorectal carcinoma  22 (6.5)
Hematologic malignancies 11 (3.3)
Hepatic cancer 6 (1.8)
Renal cell carcinoma  26 (7.7)
Lung cancer 84 (24.9)
Malignant bone tumor 2 (0.6)
Melanoma 6 (1.8)
Multiple myeloma 38 (11.3)
Neuroendocrine carcinoma 6 (1.8)
Others 24 (7.1)
Other squamous cell carcinoma 4 (1.2)
Ovarian carcinoma 3 (0.9)
Prostate carcinoma 22 (6.5)
Gastric cancer 2 (0.6)
Thyroid cancer 7 (2.1)
Cancer of unknown primary site 30 (8.9)
Uterine carcinoma 3 (0.9)
Table 7. Predictive factors that affected the odds of complications
Tested  Factors  for
Complications
Subcategory  Type of Complication  P Value OR  95% CI
Age 50-60 years Bleeding 0.014  0.53 0.30-0.89
KPS 10%-40% Bleeding 0.042 1.69 1.00-2.84
Affected  vertebral
level 
Cervical Need for postoperative
intensive care 
<1e-6  6.62 2.82-15.92
Affected  vertebral
level 
Thoracic Need for postoperative
intensive care 
0.005 0.33 0.14-0.76
Affected  vertebral
level 
Lumbal Need for postoperative
intensive care 
0.027 0.32 0.09-0.89
Type  of  primary
tumor 
Renal Bleeding 0.009 3.11 1.27-7.96
Type  of  primary
tumor 
Prostate Bleeding 0.047 0.33 0.08-1.03
Main operative step Corpectomy Bleeding <1e -6 3.25 2.03-5.25
OR, odds ratio; CI, confidence interval; KPS, Karnofsky performance scale.
